GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomarin Pharmaceutical Inc (LTS:0HNC) » Definitions » Accounts Receivable

Biomarin Pharmaceutical (LTS:0HNC) Accounts Receivable : $637 Mil (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Biomarin Pharmaceutical Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Biomarin Pharmaceutical's accounts receivables for the quarter that ended in Mar. 2024 was $637 Mil.

Accounts receivable can be measured by Days Sales Outstanding. Biomarin Pharmaceutical's Days Sales Outstanding for the quarter that ended in Mar. 2024 was 89.61.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Biomarin Pharmaceutical's Net-Net Working Capital per share for the quarter that ended in Mar. 2024 was $1.55.


Biomarin Pharmaceutical Accounts Receivable Historical Data

The historical data trend for Biomarin Pharmaceutical's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomarin Pharmaceutical Accounts Receivable Chart

Biomarin Pharmaceutical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Accounts Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 377.40 448.35 373.40 461.32 633.70

Biomarin Pharmaceutical Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Accounts Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 597.91 610.22 572.50 633.70 637.16

Biomarin Pharmaceutical Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.


Biomarin Pharmaceutical Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Biomarin Pharmaceutical's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=637.163/648.833*91
=89.61

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Biomarin Pharmaceutical's accounts receivable are only considered to be worth 75% of book value:

Biomarin Pharmaceutical's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2024 is calculated as:

Net-Net Working Capital Per Share
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(1046.58+0.75 * 637.163+0.5 * 1137.982-1798.857
-0-0)/189.777
=1.55

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.


Biomarin Pharmaceutical Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Biomarin Pharmaceutical's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Biomarin Pharmaceutical (LTS:0HNC) Business Description

Traded in Other Exchanges
Address
770 Lindaro Street, San Rafael, CA, USA, 94901
BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the U.S. in 2023.

Biomarin Pharmaceutical (LTS:0HNC) Headlines

No Headlines